We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Avoid Betting on Danaher Stock Right Now
Read MoreHide Full Article
Danaher Corporation (DHR - Free Report) has failed to impress investors with its recent operational performance due to weakness across its businesses and high operational expenses.
Based in Washington, DC, Danaher is engaged in designing, manufacturing and marketing medical, research and industrial products and services throughout the world.
Let’s discuss the factors that continue taking a toll on the firm.
Factors Affecting DHR Stock
Business Weakness: Despite recovery, sluggish demand across the pharma and biotech markets in China has been weighing on Danaher’s Instrument businesses under the Life Sciences segment. The company has been witnessing a sales decline in mass spectrometry, flow cytometry & lab automation solutions and microscopy businesses due to soft demand for equipment in major end-markets. Core revenues from the Life Sciences segment declined 2% on a year-over-year basis in 2024. Softness in the genomics consumables business, owing to tepid sales in the gene reading and proteins product lines, remains concerning for the segment.
Also, weakness in the Biotechnology segment raises concerns for the company. Sluggish demand in the discovery and medical business has been weighing on the performance of the Biotechnology segment. The segment’s core revenues declined 4.5% on a year-over-year basis in 2024. Despite improvement, equipment demand remained subdued as customers remained cautious with their capital spending.
For the first quarter of 2025, Danaher expects its adjusted core sales from continuing operations to decline in low-single digits on a year-over-year basis.
Rising Costs & Expenses: The company’s selling, general and administrative (SG&A) expenses increased 5.9% year over year in 2024 due to the impact of the Abcam acquisition. The metric, as a percentage of net sales, increased 180 basis points to 32.5% in the year. Escalating expenses if not controlled are likely to hurt the company’s bottom line in the quarters ahead.
High Debt Levels: Danaher exited fourth-quarter 2024 with a long-term debt of $15.5 billion. Its current liabilities were $6.8 billion, higher than the cash equivalents of $2.1 billion. Also, interest expenses in 2024 remained high at $278 million. High debt levels can increase its financial obligations and prove detrimental to profitability in the quarters ahead.
DHR Stock’s Price Performance
Image Source: Zacks Investment Research
Over the past six months, the Zacks Rank #4 (Sell) company’s shares have plunged 24.7% compared with the industry’s 15% decline.
Estimate Revisions: In the past 60 days, the Zacks Consensus Estimate for Danaher’s 2025 earnings has trended down from $8.31 per share to $7.63 on 12 downward estimate revisions against none upward. The consensus estimate for 2026 earnings decreased from $9.19 per share to $8.57 on seven downward estimate revisions against none upward.
Key Picks
Some better-ranked stocks from the same space are discussed below:
The company delivered a trailing four-quarter average earnings surprise of 19.4%. In the past 60 days, the Zacks Consensus Estimate for MD’s 2025 earnings has increased 4.8%.
Cencora, Inc. (COR - Free Report) currently carries a Zacks Rank #2 (Buy). COR delivered a trailing four-quarter average earnings surprise of 5%.
In the past 60 days, the consensus estimate for Cencora’s fiscal 2025 (ending September 2025) earnings has increased 2.5%.
Enhabit, Inc. (EHAB - Free Report) presently carries a Zacks Rank of 2. The company delivered a trailing four-quarter average earnings surprise of 2.9%.
In the past 60 days, the Zacks Consensus Estimate for EHAB’s 2025 earnings has increased 25%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Avoid Betting on Danaher Stock Right Now
Danaher Corporation (DHR - Free Report) has failed to impress investors with its recent operational performance due to weakness across its businesses and high operational expenses.
Based in Washington, DC, Danaher is engaged in designing, manufacturing and marketing medical, research and industrial products and services throughout the world.
Let’s discuss the factors that continue taking a toll on the firm.
Factors Affecting DHR Stock
Business Weakness: Despite recovery, sluggish demand across the pharma and biotech markets in China has been weighing on Danaher’s Instrument businesses under the Life Sciences segment. The company has been witnessing a sales decline in mass spectrometry, flow cytometry & lab automation solutions and microscopy businesses due to soft demand for equipment in major end-markets. Core revenues from the Life Sciences segment declined 2% on a year-over-year basis in 2024. Softness in the genomics consumables business, owing to tepid sales in the gene reading and proteins product lines, remains concerning for the segment.
Also, weakness in the Biotechnology segment raises concerns for the company. Sluggish demand in the discovery and medical business has been weighing on the performance of the Biotechnology segment. The segment’s core revenues declined 4.5% on a year-over-year basis in 2024. Despite improvement, equipment demand remained subdued as customers remained cautious with their capital spending.
For the first quarter of 2025, Danaher expects its adjusted core sales from continuing operations to decline in low-single digits on a year-over-year basis.
Rising Costs & Expenses: The company’s selling, general and administrative (SG&A) expenses increased 5.9% year over year in 2024 due to the impact of the Abcam acquisition. The metric, as a percentage of net sales, increased 180 basis points to 32.5% in the year. Escalating expenses if not controlled are likely to hurt the company’s bottom line in the quarters ahead.
High Debt Levels: Danaher exited fourth-quarter 2024 with a long-term debt of $15.5 billion. Its current liabilities were $6.8 billion, higher than the cash equivalents of $2.1 billion. Also, interest expenses in 2024 remained high at $278 million. High debt levels can increase its financial obligations and prove detrimental to profitability in the quarters ahead.
DHR Stock’s Price Performance
Image Source: Zacks Investment Research
Over the past six months, the Zacks Rank #4 (Sell) company’s shares have plunged 24.7% compared with the industry’s 15% decline.
Estimate Revisions: In the past 60 days, the Zacks Consensus Estimate for Danaher’s 2025 earnings has trended down from $8.31 per share to $7.63 on 12 downward estimate revisions against none upward. The consensus estimate for 2026 earnings decreased from $9.19 per share to $8.57 on seven downward estimate revisions against none upward.
Key Picks
Some better-ranked stocks from the same space are discussed below:
Pediatrix Medical Group, Inc. (MD - Free Report) presently sports a Zacks Rank # 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The company delivered a trailing four-quarter average earnings surprise of 19.4%. In the past 60 days, the Zacks Consensus Estimate for MD’s 2025 earnings has increased 4.8%.
Cencora, Inc. (COR - Free Report) currently carries a Zacks Rank #2 (Buy). COR delivered a trailing four-quarter average earnings surprise of 5%.
In the past 60 days, the consensus estimate for Cencora’s fiscal 2025 (ending September 2025) earnings has increased 2.5%.
Enhabit, Inc. (EHAB - Free Report) presently carries a Zacks Rank of 2. The company delivered a trailing four-quarter average earnings surprise of 2.9%.
In the past 60 days, the Zacks Consensus Estimate for EHAB’s 2025 earnings has increased 25%.